Rita S. Simões
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rita S. Simões has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- M. Joana F. Pinheiro
Department of Bioengineering, Instituto de Bioengenharia e Biociências (iBB), Instituto Superior Técnico, Avenida Rovisco Pais, 1049-001 Lisboa, Portugal
1 shared publication - Maria Fernanda Nascimento Neves Carvalho
Centro de Química Estrutural, Institute of Molecular Sciences and Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
1 shared publication - Nuno A. Pedro
Department of Bioengineering, Institute of Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
1 shared publication - Nuno Pereira Mira
Universidade de Lisboa Av. Rovisco Pais
1 shared publication - Sara Barbosa Salazar
Gulbenkian Institute for Molecular Medicine (GIMM), Oeiras, Portugal
1 shared publication
Latest Publications
- Open Access
- 10 February 2020
- Published by MDPI AG in Journal of Fungi
- Vol. 6 (1) , 23
An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains
Fungal infections and, in particular, those caused by species of the Candida genus, are growing at an alarming rate and have high associated rates of mortality and morbidity. These infections, generally referred as candidiasis, range from common superficial rushes caused by an overgrowth of the yeasts in mucosal surfaces to life-threatening disseminated mycoses. The success of currently used antifungal drugs to treat candidiasis is being endangered by the continuous emergence of resistant strains, specially among non-albicans Candida species. In this review article, the mechanisms of action of currently used antifungals, with emphasis on the mechanisms of resistance reported in clinical isolates, are reviewed. Novel approaches being taken to successfully inhibit growth of pathogenic Candida species, in particular those based on the exploration of natural or synthetic chemicals or on the activity of live probiotics, are also reviewed. It is expected that these novel approaches, either used alone or in combination with traditional antifungals, may contribute to foster the identification of novel anti-Candida therapies.
- 10 February 2020
- Published by MDPI AG in Journal of Fungi
- Vol. 6 (1) , 23
Open AccessAn Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains
Fungal infections and, in particular, those caused by species of the Candida genus, are growing at an alarming rate and have high associated rates of mortality and morbidity. These infections, generally referred as candidiasis, range from common superficial rushes caused by an overgrowth of the yeasts in mucosal surfaces to life-threatening disseminated mycoses. The success of currently used antifungal drugs to treat candidiasis is being endangered by the continuous emergence of resistant strains, specially among non-albicans Candida species. In this review article, the mechanisms of action of currently used antifungals, with emphasis on the mechanisms of resistance reported in clinical isolates, are reviewed. Novel approaches being taken to successfully inhibit growth of pathogenic Candida species, in particular those based on the exploration of natural or synthetic chemicals or on the activity of live probiotics, are also reviewed. It is expected that these novel approaches, either used alone or in combination with traditional antifungals, may contribute to foster the identification of novel anti-Candida therapies.